Natco Pharma Ltd. — Regulatory Filings 2021

Jan 4, 2021

==> picture [449 x 47] intentionally omitted <==

January 4, 2021

The Manager Manager – Listing DCS-LISTING M/s. National Stock Exchange of India Ltd M/s. BSE Ltd “Exchange Plaza”, Phiroze Jeejeebhoy Towers Bandra – Kurla Complex Dalal Street, Bandra (E) Mumbai 400 001 Mumbai -400 051

Scrip Code: 524816 Scrip Code: NATCOPHARM

Dear Sir,

Please find enclosed herewith Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the quarter ended December 31, 2020

Kindly acknowledge receipt of the same .

Thanking you

Yours faithfully For NATCO Pharma Limited

==> picture [106 x 22] intentionally omitted <==

M Adinarayana Company Secretary & Vice President (Legal & Corporate Affairs)

Encl. As Above.

==> picture [526 x 96] intentionally omitted <==

To, Date: 04.01.2021 The Company Secretary, Natco Pharma Limited, Natco House, Road No.2, Banjara Hills, Hyderabad – 500 034

Sub: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31.12.2020

Ref : Security Code - 524816ISIN : INE987B01026

Dear Sir/Madam,

We hereby certify that the securities received for dematerialisation have been mutilated and cancelled after due verification and the name of the depositories (National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) has been updated in the records of company as the registered owner within 15 days of receipt of valid DRF & Share certificate of said company and the details of securities are furnished to the stock exchange(s).

We request you to take this information on record and to inform Depositories(s) and Stock Exchange(s) wherever your securities are listed accordingly.

Thanking you,

Yours faithfully,

For Venture Capital and Corporate Investments Private Limited.

==> picture [45 x 22] intentionally omitted <==

Authorised Signatory.

==> picture [528 x 37] intentionally omitted <==